News
GlobalData on MSN11h
Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpointAmgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab in combination with ...
Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback